Annika Mehlem

This inventor holds 4 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: B-Creative Sweden Ab, Csl Limited. Active years: 2017-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Annika Mehlem. Retrieved from https://idiyas.com/inventor/annika-mehlem

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 4 (Patent Applications = 3)

% Patents Active = 75.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2017-2022

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11261243 - Methods of treating diabetic nephropathy by administering an anti-vegf-b (vascular endothelial growth factor-b) antibody (2022-03-01),

2. 10543270 - Methods of treating wounds in a diabetic subject (2020-01-28),

3. 10407498 - Method of treating diabetic nephropathy in a subject suffering from type 2 diabetes by administering an antibody which inhibits VEGF-B signaling (2019-09-10),

4. 9803008 - Method of treating diabetic nephropathy by administering antibodies to vascular endothelial growth factor B (VEGF-B) (2017-10-31),

Title: Annika Mehlem: Innovator in Diabetic Treatment

Introduction

Annika Mehlem is a prominent inventor based in Stockholm, Sweden. She has made significant contributions to the field of medical treatments, particularly focusing on diabetic conditions. With a total of four patents to her name, her work is paving the way for innovative therapies.

Latest Patents

Among her latest patents, Annika has developed methods for treating diabetic nephropathy by administering an anti-VEGF-B (vascular endothelial growth factor-B) antibody. This method provides a novel approach to treating subjects suffering from diabetic nephropathy by inhibiting VEGF-B signaling. Additionally, she has created methods for treating wounds in diabetic subjects, which also involve administering compounds that inhibit VEGF-B signaling. These advancements are crucial for improving the quality of life for individuals with diabetes.

Career Highlights

Throughout her career, Annika has worked with notable companies such as CSL Limited and B-Creative Sweden AB. Her experience in these organizations has allowed her to refine her skills and contribute to groundbreaking research in her field.

Collaborations

Annika has collaborated with esteemed colleagues, including Ulf Eriksson and Annelie Falkevall. These partnerships have enhanced her research and led to significant advancements in diabetic treatment methodologies.

Conclusion

Annika Mehlem's innovative work in the treatment of diabetes showcases her dedication to improving patient outcomes. Her patents and collaborations reflect her commitment to advancing medical science.

Profile summary based on public USPTO records.